© UK Bioindustry Association 2017UK's Bioscience Industry Braves Brexit

January 2018. The British BioIndustry Association (BIA) and Informa Pharma Intelligence published a report Pipeline Progressing: the UK’s global bioscience cluster in 2017  1)  which shows that the UK has the strongest clinical and preclinical pipeline in Europe. It also shows that more UK biotech companies are maturing and moving through the financing life cycle, with UK biotech company IPOs raising more than twice as much money in 2017 than in 2016.

Key statistics from Report© Informa pharma intelligence 2018 life science industry Europe VC raised 2017
• The UK has the strongest pipeline in Europe across all preclinical and clinical stages, with 351 preclinical products, 43 phase I, 70 phase II and 15 phase III
• UK biotech company IPOs raised more than twice as much money in 2017 (£234m) than in 2016 (£105m)
• UK biotech raised more on the public markets than in venture capital as UK companies matured and progressed through the funding lifecycle with £515m raised in venture capital, £234m raised in IPOs and £452m raised in follow on funding
• LSE’s Main Market has seen major indirect investment through vehicles that fund the biopharma sector including Arix Bioscience (£113m) and Biopharma Credit (£606m)
• The 2017 IPO listings on Nasdaq (NuCana plc, Nightstar Therapeutics and Verona) show that there is global demand for UK biotech companies

Outlook
Stephen N. Bates, CEO of BIA is pleased to see “the UK biotech ecosystem to produce fantastic science that attracts talent and funding from across the globe.  There is money to be made as this pipeline develops. The Patient Capital Review  2)  means 2018 is the year UK pension funds will be nudged into backing this key sector of the future UK economy." The author of the report, John Hodgson brought some encouragement to the British life science industry: "Despite Brexit, UK biopharma investment is internationalising. London's markets provide cash for biotech globally, UK biotechs access international money, and venture capital has migrated upstream."

 

References added by B2Bioworld
1)
Hodgson (2018): Pipeline Progressing: The UK’s Global Bioscience Cluster in 2017. London, January 25: UK BioIndustry Association / Informa Pharma Intelligence

2) UK Treasury (2017): Terms of Reference for the Patient Capital Review. London, November 22: https://www.gov.uk/government/publications/patient-capital-review/terms-of-reference-for-the-patient-capital-review

Source: UK BioIndustry Association / Informa 

Back to section

Related Editorial Articles

B2Bioworld offers you background information

The Great Br // Exit: Transatlantic Commonwealth

Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Plant Genetic Engineering:”It’s not as simple as Yes or No!”
Nobel Prize winner Christiane Nüsslein-Volhard Warns of GMO-populism and researchers not standing up

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Horizon Discovery: Mitigating risks and developing the U.S. business

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts

“Grande gueule” and the fallout of Brexit, CETA, or Trumpeta
Jan Peumans, President of the Belgium’s Flemish Parliament about regional politics in uncertain times for international trade

Sandro Aruffo’s Syngenta Legacy
The late Head of R&D and Robert Berendes, Head of Business Development in a candid conversation about plant biotechnology, cross-fertilization with organic farming, agrichemicals, and prospects in Africa and Asia

CETA: “Of course, implementation!”
Philippe Couillard, Premier of Québec and Pierre-Marc Johnson, Chief Negotiator of the Province for the EU-Canada free trade agreement

UK Chemical Industries’ Lessons from the Recession
John Saul, past President of the British Chemical Industries Association on Issues for a Sustainable Future of the Sector

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.